|
Just received:
Interim analysis of attached Phase I/II Study of Rexin-G for Breast
Cancer:
Analysis of "Treated" Patients: There were 6 evaluable patients. Five of
six evaluable patients had stable disease as their best objective
response by RECIST criteria at 4-6 weeks after treatment initiation.
Using the International PET criteria, 2/6 patients had a partial
response (PR) and 4/6 patients had SD. Taken together, all 6 evaluable
patients had a positive response by PET Criteria. Three patients had
surgical resection of their tumors after at least 4 cycles of Rexin-G.
Post surgical resection, one has no evidence of disease, and two have
stable residual disease. One patient continues on the 9th cycle of
Rexin-G, living now for 13 months after Rexin-G treatment initiation on
Aug. 18, 2007. Median progression-free survival by RECIST was 6 months,
and median over-all survival was >9.5 months.
If you are interested in participating in this study, please call Vickie
Chua, clinical trials coordinator, at 310-552-9999.
Erlinda M. Gordon, M.D.
Vice President, Operations and Medical Affairs
Epeius Biotechnologies Corporation
475 Huntington Drive
San Marino CA 91108
Tel: 626-441-6695; Fax: 626-441-6692
|